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Background: Combining two long-acting bronchodilators with complementary mechanisms of action may provide
treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those
derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium
bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting β2-agonist, in patients with
moderate to severe COPD are presented.
Methods: In this 24-week double-blind study, 1692 patients with stable COPD were equally randomized to twice-daily
treatment with FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC), FDC aclidinium 400 μg/formoterol 6 μg
(ACL400/FOR6 FDC), aclidinium 400 μg, formoterol 12 μg, or placebo administered by a multidose dry powder inhaler
(Genuair®/Pressair®)*. Coprimary endpoints were change from baseline to week 24 in 1-hour morning postdose FEV1
(FDCs versus aclidinium) and change from baseline to week 24 in morning predose (trough) FEV1 (FDCs versus
formoterol). Secondary endpoints were change from baseline in St. George’s Respiratory Questionnaire (SGRQ)
total score and improvement in Transition Dyspnea Index (TDI) focal score at week 24. Safety and tolerability
were also assessed.
Results: At study end, improvements from baseline in 1-hour postdose FEV1 were significantly greater in
patients treated with ACL400/FOR12 FDC or ACL400/FOR6 FDC compared with aclidinium (108 mL and
87 mL, respectively; p < 0.0001). Improvements in trough FEV1 were significantly greater in patients treated
with ACL400/FOR12 FDC versus formoterol (45 mL; p = 0.0102), a numerical improvement of 26 mL in trough
FEV1 over formoterol was observed with ACL400/FOR6 FDC. Significant improvements in both SGRQ total
and TDI focal scores were observed in the ACL400/FOR12 FDC group at study end (p < 0.0001), with differences over
placebo exceeding the minimal clinically important difference of ≥4 points and ≥1 unit, respectively. All treatments
were well tolerated, with safety profiles of the FDCs similar to those of the monotherapies.
Conclusions: Treatment with twice-daily aclidinium 400 μg/formoterol 12 μg FDC provided rapid and sustained
bronchodilation that was greater than either monotherapy; clinically significant improvements in dyspnea and
health status were evident compared with placebo. Aclidinium/formoterol FDC may be an effective and well
tolerated new treatment option for patients with COPD.
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In patients with chronic obstructive pulmonary disease
(COPD), combining bronchodilators with complementary
mechanisms of action has the potential to increase lung
function and improve symptom management compared
to treatment with a single agent [1]. Inhaled long-acting
muscarinic antagonists (LAMAs) and long-acting β2-
agonists (LABAs) are widely used as maintenance treatment
in COPD. LAMAs indirectly reduce bronchoconstriction by
inhibiting acetylcholine signaling via muscarinic receptors
on airway smooth muscle, while LABAs directly stimulate
β2-adrenoceptors that lead to smooth muscle relaxation.
Though the mechanisms of action of these two classes of
bronchodilators differ, LAMA/LABA combinations have
been a successful treatment option for patients with COPD,
improving both spirometric values and health-related quality
of life [2-4].
Current treatment guidelines recommend LAMA/
LABA combination therapy for COPD patients uncontrolled
by bronchodilator monotherapy [1]. Studies investigating
the free combination of LAMA and LABA therapies (via
two separate inhalers) in patients with COPD have
shown improved bronchodilation and reduced rescue
medication use compared with monotherapy [2,3,5,6].
Treatment with either aclidinium bromide (a LAMA)
400 μg twice-daily (BID) or formoterol fumarate (a
LABA) 12 μg twice daily improves lung function and
reduces COPD symptoms while being well tolerated
[7-12]. As treatment with aclidinium also has been
shown to improve health status, exercise endurance,
and nighttime symptoms in patients with COPD
[11,13], a fixed-dose combination (FDC) comprising
aclidinium bromide/formoterol fumarate (Genuair®/
Pressair®*, approved for delivery of aclidinium monotherapy)
may improve lung function, health status, and COPD
symptoms while reducing the potential risk for side effects
that often occur from increasing doses of monotherapy
treatments [1].
The efficacy and safety of twice-daily aclidinium/
formoterol FDC in patients with moderate to severe
COPD were assessed in a 24-week phase 3, randomized,
double-blind study (AUGMENT COPD, Aclidinium/
formoterol FUmarate Combination for InvestiGative use
in the TreatMENT of Moderate to Severe COPD), the
results of which are presented here.Methods
Study design
This phase 3, randomized, double-blind study in patients
with moderate to severe COPD was conducted in 222
centers throughout North America, Australia, and New
Zealand (NCT01437397) in accordance with the
International Conference on Harmonization/Good Clinical
Practice guidelines and the Declaration of Helsinki. The
protocol was approved by the Institutional Review
Board at each study center, and all patients gave written
informed consent before participating in any study
procedures. The study comprised a 2- to 3-week run-in
period prior to a 24-week double-blind treatment period
(Figure 1). Patients were equally randomized to twice-
daily aclidinium/formoterol FDC 400/12 μg, aclidinium/
formoterol FDC 400/6 μg, aclidinium 400 μg, formoterol
12 μg, or placebo, administered via a multidose, dry-powder
inhaler (Genuair®/Pressair®)*. The first patient/first visit
was October 4, 2011 and the last patient completed
February 6, 2013.
Patients
Patients aged ≥40 years were eligible if they were current
or former smokers (≥10 pack-years) and diagnosed with
stable, moderate to severe expiratory airflow obstruction
according to GOLD guidelines (postbronchodilator forced
expiratory volume in 1 second [FEV1]/forced vital capacity
[FVC] <70% and FEV1 ≥30% and <80% predicted) [1].
Main exclusion criteria were: COPD exacerbation or
respiratory tract infection ≤6 weeks (≤3 months if
hospitalized for exacerbation) before screening; clinically
significant respiratory conditions (including asthma);
clinically significant cardiovascular (CV) conditions
including myocardial infarction (MI) within the previous
6 months; unstable angina; and, unstable arrhythmia
that required changes in pharmacological therapy or
other intervention within the previous 6 months. Use
of long-acting bronchodilators other than investigative
treatment was not permitted. Other COPD medications,
such as theophylline, inhaled corticosteroids (ICS),
oral or parenteral corticosteroids (≤10 mg/day or
20 mg every other day of prednisone) were allowed if
treatment was stable ≥4 weeks prior to screening. Use
of albuterol/salbutamol as rescue medication was
permitted.
Figure 1 Study design. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 12 μg; ACL400/FOR6 FDC, fixed-dose
combination of aclidinium 400 μg and formoterol 6 μg; D, day; Wk, week.
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Coprimary efficacy parameters, assessed by standardized
spirometric measurements of lung function [14], were
change from baseline to week 24 in 1-hour morning
postdose FEV1 (each FDC versus aclidinium, contribution
of formoterol) and change from baseline to week 24 in
morning predose (trough) FEV1 (each FDC versus formoterol,
contribution of aclidinium). Secondary efficacy parameters
were change from baseline in St. George’s Respiratory
Questionnaire (SGRQ) total score at week 24 (each FDC
versus placebo) and improvement in Transition Dyspnea
Index (TDI) focal score at week 24 (each FDC versus
placebo).
Additional treatment comparisons for each coprimary
parameter included: each aclidinium/formoterol FDC dose
versus each monotherapy; each active treatment versus
placebo; and aclidinium/formoterol FDC 400/12 μg versus
aclidinium/formoterol FDC 400/6 μg. Additional efficacy
parameters included: change from baseline in peak FEV1
at all visits; 12-hour spirometry measurements (in a subset
of the intention-to-treat [ITT] population) based on
change from baseline in FEV1 at all study visits; SGRQ
and Baseline/Transition Dyspnea Index (BDI/TDI) at all
study visits except week 24; rescue medication use; onset
of action of bronchodilation; and, daily COPD symptoms
assessed by the Exacerbations of Chronic Pulmonary
Disease Tool (EXACT)-Respiratory Symptoms (E-RS)
questionnaire [15]. A Nighttime Symptoms of COPD
Instrument (NiSCI) [16,17] and an Early Morning Symptoms
of COPD Instrument (EMSCI) [18]—newly developed
patient reported outcome measures undergoing empirical
testing—were completed twice daily by patients using the
electronic diary.
Safety was assessed through reporting of adverse
events (AEs), clinical laboratory tests, vital signs,electrocardiograms (ECGs), and 24-hour 12-lead Holter
monitoring. Major adverse cardiovascular events (MACE)
were defined as the composite of CV deaths, nonfatal
MIs, and nonfatal strokes. MACE were evaluated and
classified by an adjudication committee of independent
cardiologists who were not participating in the study and
were blinded to treatment. To identify all MACE, a list of
all AEs that were reported in randomized patients based
on standard medical dictionary for regulatory activities
(MedDRA) queries of cardiac disorders and cerebrovascular
disorders was used.
Assessments for all efficacy and safety outcomes
occurred at various timepoints throughout the study
(Additional file 1: Table S1).
Statistical analysis
Statistical analyses were performed using SAS® version
9.2. All efficacy analyses with the exception of E-RS were
based on the ITT population, defined as all randomized
patients who took ≥1 dose of study medication and had
a baseline and at least one postbaseline FEV1 assessment.
E-RS data were analyzed for the ITT-Exacerbation
Population, which included all patients in the randomized
population who took at least 1 dose of double-blind
investigational product. Change from baseline in broncho-
dilation outcomes were analyzed by mixed model for
repeated measures (MMRM) with treatment group, sex,
smoking status, visit, and treatment-group-by-visit interaction
as fixed-effect factors and corresponding baseline values
and age as covariates, and pre- and postbronchodilator
FEV1 as a covariate for FEV1 outcomes. A sample size of
1550 (310 per randomized group) was estimated to provide
at least 90% power to detect a statistically significant
treatment difference of 100 mL (standard deviation of
280 mL) between each FDC dose versus aclidinium
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postdose FEV1 at week 24, and 65 mL (standard deviation
of 240 mL) between each FDC dose versus formoterol
monotherapy in the change from baseline in morning pre-
dose (trough) FEV1 at week 24. To control for family-wise
type 1 error rate at the 2-sided 5% significance level for the
primary and secondary efficacy endpoints, a prespecified
multiple comparison strategy was conducted.
The onset of action of bronchodilation in FEV1 (an
additional endpoint defined as a >15% increase from
baseline in FEV1) from 5-minutes to 3-hours postdose on
day 1 was evaluated using a logistic regression model with
treatment groups, sex, and smoking status as fixed-effect
factors and pre- and postbronchodilator FEV1 at screening,
age, and baseline FEV1 as covariates. Odds ratios were
estimated for each treatment group versus placebo. Change
from baseline in TDI and SGRQ were analyzed using
a MMRM as described for bronchodilation outcomes.
A logistic random-effect model was used to analyze
the number and percentage of patients who achieved
a clinically meaningful improvement from baseline in
SGRQ total score (decrease of ≥4 units) [19] or in
TDI focal score (increase of ≥1 unit). Use of rescue
medication was analyzed using averages of the daily
diary values over the time periods between visits and
were based on the change from baseline values. Daily
COPD symptoms were analyzed by means of an MMRM
adjusted for baseline, treatment, visit, sex, age, smoking
status, and treatment-by-visit interaction. Safety results,
summarized descriptively, were based on the safety
population, defined as all randomized patients who took
≥1 dose of study medication.Figure 2 Patient disposition. *Study terminated by Sponsor; ACL400/FOR
12 μg; ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400 μg a
ITT, intention-to-treat.Results
Patient disposition and baseline characteristics
A total of 1692 patients were randomized (Figure 2).
Completion rates were highest with aclidinium/formoterol
FDC 400/12 μg (80.5%) and aclidinium/formoterol FDC
400/6 μg (81.7%) and lowest with placebo (70.0%). Study
discontinuations among randomized groups were most
frequently due to AEs, protocol violation, and withdrawal
of consent. A total of 5.9% of patients in the placebo group
discontinued due to insufficient therapeutic response.
Among the active treatment groups, discontinuations due
to insufficient response were 2.9% for formoterol, 2.4% for
aclidinium, and 1.5% and 1.2% for the aclidinium/
formoterol FDC 400/12 μg and 400/6 μg groups.
Patient demographics and baseline characteristics were
similar across groups (Table 1). The average patient age
was 63.9 years, 53.1% were male, and 93.2% were white.
Average postbronchodilator FEV1% predicted at screening
was 53.5% and baseline FEV1 was 1.37 L. There were no




Treatment with both aclidinium/formoterol FDC doses
resulted in clinically meaningful and significant improvements
in lung function, measured by the change from baseline to
week 24 in 1-hour postdose FEV1 versus aclidinium
monotherapy (coprimary endpoint), with least squares (LS)
mean treatment differences of 108 mL (aclidinium/formoterol
FDC 400/12 μg) and 87 mL (aclidinium/formoterol FDC
400/6 μg) (Figure 3A, p < 0.0001). At all timepoints from12 FDC, fixed-dose combination of aclidinium 400 μg and formoterol
nd formoterol 6 μg; COPD, chronic obstructive pulmonary disease;
Table 1 Demographic and baseline characteristicsa
Characteristics, mean (SD)b PBO (n = 332) ACL400/FOR12
FDC (n = 335)
ACL400/FOR6
FDC (n = 333)
ACL 400 (n = 337) FOR 12 (n = 332)
Age, years 63.5 (8.9) 64.2 (8.9) 63.9 (9.2) 64.4 (8.7) 63.7 (8.7)
Male, n (%) 175 (52.7) 168 (50.1) 187 (56.2) 188 (55.8) 169 (50.9)
White, n (%) 317 (95.5) 305 (91.0) 309 (92.8) 314 (93.2) 311 (93.7)
Current smoker, n (%) 169 (50.9) 173 (51.6) 176 (52.9) 171 (50.7) 171 (51.5)
Smoking history, pack-years 53.3 (28.5) 53.3 (27.2) 52.1 (25.8) 52.0 (26.1) 52.5 (23.7)
Prebronchodilator FEV1, L 1.35 (0.54) 1.34 (0.53) 1.40 (0.54) 1.34 (0.53) 1.37 (0.52)
Postbronchodilator FEV1,
% of predicted
52.6 (13.3) 53.2 (13.4) 54.7 (12.9) 53.0 (13.3) 53.9 (13.1)
Bronchial reversibility, % 18.4 (15.2) 17.2 (14.6) 17.7 (15.0) 19.1 (16.5) 17.3 (14.7)
COPD severity, n (%)c
Moderate 177 (53.3) 189 (56.4) 203 (61.0) 184 (54.6) 197 (59.3)
Severe 150 (45.2) 142 (42.4) 127 (38.1) 147 (43.6) 131 (39.5)
Baseline efficacy variablesd
SGRQ total score 45.3 (17.9) 47.6 (16.9) 46.2 (17.9) 45.2 (17.8) 45.8 (17.9)
BDI focal score 6.4 (2.4) 6.2 (2.1) 6.5 (2.2) 6.5 (2.3) 6.3 (2.3)
Rescue medication use, puffs/day 4.2 (3.9) 4.5 (3.7) 4.0 (3.3) 4.0 (3.4) 4.3 (3.7)
EXACT-RS score 11.03 (5.84) 11.89 (6.51) 11.46 (6.25) 11.27 (6.33) 11.40 (6.57)
NiSCI score 0.95 (0.63) 1.10 (0.70) 0.99 (0.69) 1.00 (0.70) 0.99 (0.71)
EMSCI score 1.07 (0.58) 1.19 (0.63) 1.15 (0.64) 1.13 (0.65) 1.13 (0.66)
aFor the safety population, unless indicated otherwise; bAll results reported as mean values with standard deviations, unless indicated otherwise; cCOPD severity
based on GOLD 2011 update guidelines [32]. A small (<2%) portion of the population (not shown here) were diagnosed as having mild or very severe COPD at
baseline; dFor the intention-to-treat population: PBO, n = 331; ACL400/FOR12 FDC, n = 335; ACL400/FOR6 FDC, n = 333; ACL 400, n = 337; FOR 12, n = 332;
Total, N = 1669.
ACL 400, aclidinium 400 μg; ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 12 μg; ACL400/FOR6 FDC, fixed-dose combination
of aclidinium 400 μg and formoterol 6 μg; BDI, Baseline Dyspnea Index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second;
FOR 12, formoterol 12 μg; SGRQ, St. George’s Respiratory Questionnaire; PBO, placebo; SD, standard deviation.
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FDC 400/12 μg or aclidinium/formoterol FDC 400/6 μg
resulted in significant improvements from baseline in
1-hour postdose FEV1 compared with aclidinium, formoterol,
and placebo (Figure 3B; p < 0.01 for all). At all timepoints,
both monotherapies resulted in significantly greater
improvements from baseline compared with placebo
(p < 0.0001 for all). A numerically greater change from
baseline in 1-hour postdose FEV1 was evident for
aclidinium/formoterol FDC 400/12 μg compared with
aclidinium/formoterol FDC 400/6 μg at all timepoints,
including 24 weeks, though the improvements did not
reach statistical significance except at week 4 (p < 0.05).
Trough FEV1
Treatment with aclidinium/formoterol FDC 400/12 μg
significantly improved morning predose (trough) FEV1
from baseline compared with formoterol at week 24
(coprimary endpoint), with an LS mean difference of
45 mL (Figure 4A, p = 0.01); treatment with aclidinium/
formoterol FDC 400/6 μg resulted in a numerically
greater improvement from baseline versus formoterol
at study end (LS mean treatment difference, 26 mL;p = 0.133). Significant improvements from baseline in
trough FEV1 were observed with aclidinium/formoterol
FDC 400/12 μg compared with either monotherapy at all
timepoints (p < 0.05 for all) except week 18 and 24 versus
aclidinium (Figure 4B). At various timepoints throughout
the study, both FDCs improved trough FEV1 from
baseline versus one or both monotherapies. Compared
with placebo, both aclidinium/formoterol FDCs and the
monotherapies significantly improved trough FEV1 from
baseline at all timepoints (p < 0.0001 for all). At all
timepoints throughout the study, numerically greater
improvements from baseline were observed in trough
FEV1 for the aclidinium/formoterol FDC 400/12 μg versus
aclidinium/formoterol FDC 400/6 μg dose.
Onset of bronchodilation
Treatment with either aclidinium/formoterol FDC
resulted in rapid bronchodilation, with significant
improvements in FEV1 over aclidinium and placebo
observed within 5 minutes of the morning dose on day 1
(Figure 5A; both p < 0.0001). At week 24, FEV1 results
over the first 3 hours postdose were similar to those
observed on day 1 (Figure 5B).
Figure 3 Mean changes from baseline in 1-hour morning postdose FEV1 (A) at week 24 (coprimary endpoint) and (B) over time across
duration of study. Analyses were based on a mixed-model for repeated measures. All active treatment groups were significant versus placebo
(p < 0.0001) at all study visits. *p < 0.05 versus placebo; §p < 0.05 versus aclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose
combination of aclidinium 400 μg and formoterol 12 μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 6 μg;
D1, day 1; D4, day 4; FEV1, forced expiratory volume in 1 second; LS, least squares.
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dinium/formoterol FDC 400/12 μg (26.3%), aclidinium/
formoterol FDC 400/6 μg (23.1%), and formoterol (28.3%)
groups achieved onset of action—defined as >15%
increase from baseline in FEV1—at 5 minutes postdose
on day 1 than patients treated with aclidinium (6.5%;
p < 0.0001 for both FDCs versus aclidinium, based on
odds ratios) or placebo (2.1%; p < 0.01 all active
treatment).Peak FEV1
Compared to monotherapy, treatment with either aclidinium/
formoterol FDC resulted in sustained improvements in
lung function over the 24-week study, with significant
changes from baseline in peak FEV1 at day 1 and week 24
(p < 0.0001 all comparisons). Compared to placebo,
significant improvements in peak FEV1 from baseline were
observed with both aclidinium/formoterol FDCs at day 1
and week 24, with LS mean treatment differences of
Figure 4 Mean changes from baseline in morning predose (trough) FEV1 (A) at week 24 (coprimary endpoint) and (B) over time across
duration of study. Analyses were based on a mixed-model for repeated measures. *p < 0.05 versus placebo; ‡p < 0.05 versus formoterol and
placebo; §p < 0.05 versus aclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400 μg and formoterol
12 μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 6 μg; FEV1, forced expiratory volume in 1 second;
LS, least squares.
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400/12 μg and aclidinium/formoterol FDC 400/6 μg,
p < 0.0001) and 285 mL and 259 mL (week 24; p < 0.0001
all comparisons). Changes from baseline in peak FEV1
with aclidinium/formoterol FDC 400/12 μg were numericallygreater than those with aclidinium/formoterol FDC
400/6 μg at day 1 and week 24.
Maximal bronchodilation over placebo was achieved at
3 hours postdose on day 1 with aclidinium/formoterol
FDC 400/12 μg and aclidinium/formoterol FDC 400/6 μg
Figure 5 Mean changes from baseline in FEV1 0–3 hours (A) on day 1 and (B) at week 24. Analyses were based on a mixed-model for
repeated measures. *p < 0.05 versus placebo; †p < 0.05 versus aclidinium and placebo; §p < 0.05 versus aclidinium, formoterol, and placebo;
¥p < 0.05 versus aclidinium/formoterol FDC 400/6 and placebo. No significant differences between the two FDCs at any timepoint. ACL400/FOR12
FDC, fixed-dose combination of aclidinium 400 μg and formoterol 12 μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400 μg and
formoterol 6 μg; FEV1, forced expiratory volume in 1 second; LS, least squares.
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observed at week 24 (298 and 264 mL; all p < 0.0001
versus placebo). Significantly greater improvements in
peak FEV1 were observed on day 1 and week 24 in
patients treated with either monotherapy compared with
placebo (LS mean difference for aclidinium and formoterol:
day 1, 165 mL and 154 mL; week 24, 174 mL and 182 mL;
p < 0.0001 all comparisons).
12-hour serial spirometry substudy
In a subset of ITT patients (N = 270) who participated in
a 12-hour serial spirometry substudy, statistically significant
changes from baseline in FEV1 over placebo were observed
at most timepoints for those treated with either aclidinium/
formoterol FDC; results for both aclidinium/formoterol
FDCs were numerically greater than the monotherapies
(Additional file 1: Figure S1). Data from the serial
spirometry substudy support the results observed for
the entire ITT population and substantiates the BID
dosing regimen of the aclidinium/formoterol FDCs, as
demonstrated by the FEV1 values over the entire dosing
interval (Additional file 1: Figure S1).
Breathlessness
At week 24, significant improvements in TDI focal scores
were achieved with the aclidinium/formoterol FDCs
compared with placebo (secondary endpoint; p < 0.0001),
as well as with either aclidinium or formoterol (p ≤ 0.01
for both versus placebo; Figure 6A). Treatment with the
aclidinium/formoterol FDCs resulted in numerically greater
improvements in TDI focal scores compared to eithermonotherapy. At all other study visits, significantly greater
improvements in TDI focal scores were observed with
aclidinium/formoterol FDC 400/12 μg versus formoterol
(p < 0.01); improvements in TDI focal scores were similar
between aclidinium/formoterol FDC 400/12 μg and
aclidinium/formoterol FDC 400/6 μg.
At week 24, all active treatments reached the MCID of
1-unit improvement from baseline. The percentage of
patients who reached the MCID of ≥1-unit improvement
from baseline in TDI focal score was greater in either
aclidinium/formoterol FDC group versus placebo (p < 0.0001
based on odds ratios). Treatment with either monotherapy
also resulted in significantly greater percentages of
patients who achieved the MCID versus placebo at week
24 (p < 0.01), though greater odds ratios were observed
with the FDCs compared to either monotherapy
(Figure 6B). At week 24, average increases in TDI focal
scores beyond the MCID of 1-unit improvement over
placebo (considered a more stringent criteria than
improvements over baseline) were observed in patients
treated with either aclidinium/formoterol FDC (p < 0.0001).
Both monotherapies neared the 1-unit improvement over
placebo at week 24, with changes from baseline of 0.98 and
0.94 for aclidinium and formoterol, respectively. All active
treatment arms resulted in significantly greater percentages
of responders versus placebo throughout the study period
(Figure 6C).
Health status
At week 24, significant improvements in SGRQ total
scores from baseline were observed with the aclidinium/
Figure 6 (See legend on next page.)
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Figure 6 Improvements in TDI focal score as assessed by (A) mean changes from baseline at week 24, (B) percentage of patients who
responded at week 24, and (C) percentage of patients who responded over time. Mean changes were analyzed using a mixed-model for
repeated measures. Responders were defined as patients who had a TDI focal score improvements of ≥1 unit; ORs based on a logistic random
effect model for active treatment versus placebo. *p < 0.01 versus placebo; **p≤ 0.001 versus placebo; †p < 0.05 versus aclidinium and placebo;
‡p < 0.05 versus formoterol and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 12 μg; ACL400/FOR6
FDC, fixed-dose combination of aclidinium 400 μg and formoterol 6 μg; LS, least squares; OR, odds ratio; TDI, Transition Dyspnea Index.
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(secondary endpoint, p < 0.05; Figure 7A). At all timepoints,
a significantly greater percentage of responders (patients
achieving ≥4-unit improvement from baseline in SGRQ
total score) were observed with either aclidinium/
formoterol FDC versus placebo, including at study end
(Figure 7B, both p < 0.01).
At week 24, mean differences in SGRQ total score
over placebo (again, a more rigorous criteria than over
baseline) exceeded the MCID of 4 units in patients
treated with aclidinium/formoterol FDC 400/12 μg or
aclidinium monotherapy (week 24; p < 0.001). Compared with
placebo, treatment with either aclidinium or formoterol
resulted in a significantly greater percentage of responders
at weeks 4 and 24, while treatment with either aclidinium/
formoterol FDC resulted in significantly greater percentages
of responders at all study weeks (Figure 7C; all comparisons
p < 0.05 versus placebo).
Rescue medication use
Compared with placebo, significant reductions in the
change from baseline in overall total daily rescue
medication use over 24 weeks were observed in each active
treatment group (p < 0.0001). A numerically greater
magnitude of effect was observed in patients treated
with the aclidinium/formoterol FDCs compared to
either monotherapy (−1.11 and −1.10 puffs per day for
aclidinium/formoterol FDC 400/12 μg and 400/6 μg versus
−0.68 aclidinium and −0.90 formoterol). Improvements
from baseline in overall total daily use of rescue medication
were significantly greater for both aclidinium/formoterol
FDCs versus aclidinium alone (p < 0.01).
EXACT-RS
Over 24-weeks, significant improvements in overall
average daily EXACT-Respiratory Symptoms scores were
observed with both FDCs and the monotherapies compared
with placebo (Figure 8A; p < 0.01). The changes from
baseline in overall average daily E-RS scores were
numerically improved for aclidinium/formoterol FDC
400/12 μg and significantly improved for aclidinium/
formoterol FDC 400/6 μg versus either monotherapy
(p < 0.05). For the change from baseline in E-RS total
score, significant improvements from baseline were
observed for all active treatment groups over placebo at
all study visits (p < 0.05 for all). No consistently significantimprovements were observed for either of the FDCs
versus the monotherapies across visits, though both FDCs
showed significant improvements compared with aclidi-
nium and/or formoterol intermittently during the study.
At all assessments, the aclidinium/formoterol FDC 400/
6 μg dose resulted in numerically greater improvements
than the aclidinium/formoterol FDC 400/12 μg dose.
Nighttime symptoms of COPD
Treatment with either aclidinium/formoterol FDC
resulted in significant improvements versus placebo in
overall nighttime symptom severity, measured by the NiSCI,
at all study visits including study end (Figure 8B; p < 0.01
versus placebo). While treatment with either aclidinium
or formoterol monotherapies significantly improved night-
time symptom severity over placebo at weeks 4 and 18
(both p < 0.05), statistical significance was not met at week
24. Patients in the aclidinium/formoterol FDC treatment
groups reported greater reductions in overall nighttime
COPD symptom severity versus either monotherapy at
week 24, with results reaching statistical significance for
the aclidinium/formoterol FDC 400/6 μg versus aclidinium
(Figure 8B; p < 0.05). At all other timepoints (weeks 4, 12,
and 18), both aclidinium/formoterol FDCs resulted in
significant reductions in overall nighttime symptom severity
versus aclidinium (p < 0.05). Significant improvements versus
formoterol were observed for the aclidinium/formoterol
FDC 400/12 μg dose at weeks 4 and 18, while the
aclidinium/formoterol FDC 400/6 μg resulted in significant
improvements in this comparison at weeks 12 and 18 (all
p < 0.05). Numerically greater improvements were observed
with the FDC 400/12 dose versus the FDC 400/6 dose at
week 4.
Early morning symptoms of COPD
The average rating for overall early morning COPD symptom
severity via the EMSCI was significantly improved for
the aclidinium/formoterol FDCs compared with placebo
at all timepoints including study end (Figure 8C; p < 0.01
for all). Neither monotherapy treatment resulted in
improvements in symptom severity over placebo at any
visit with the exception of formoterol at week 4 (p < 0.01).
At week 24, the average rating for overall early morning
COPD symptom severity via the EMSCI was significantly
improved for both aclidinium/formoterol FDCs versus
aclidinium (p < 0.05), but not versus formoterol. For all
Figure 7 (See legend on next page.)
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Figure 7 Improvements in SGRQ total score as assessed by (A) mean changes from baseline at week 24, (B) percentage of patients
who responded at week 24, and (C) percentage of patients who responded over time. Mean changes were analyzed using a mixed-model
for repeated measures. Responders were defined as patients who had a ≥4-point improvement from baseline in SGRQ total score, with ORs based
on a logistic random effect model for active treatment versus placebo. *p < 0.05 versus placebo; **p≤ 0.001 versus placebo. ACL400/FOR12 FDC,
fixed-dose combination of aclidinium 400 μg and formoterol 12 μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400 μg and
formoterol 6 μg; LS, least squares; OR, odds ratio; SGRQ, St. George’s Respiratory Questionnaire.
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significantly reduced early morning symptom severity
compared with either monotherapy (p ≤ 0.01 for all),
except at week 4 for aclidinium/formoterol FDC 400/12 μg
versus formoterol. Improvements observed between the
aclidinium/formoterol FDCs were similar throughout
the study.
Safety
The overall incidence of treatment-emergent AEs (TEAEs)
with aclidinium/formoterol FDCs was similar to those of
aclidinium and numerically greater than formoterol, with
no apparent dose-related trends between the higher and
lower FDC doses. The most commonly reported TEAEs
(≥5% of patients in any treatment group) were cough and
nasopharyngitis (Table 2). The majority of TEAEs were
mild or moderate in severity and were considered unrelated
to treatment by trial investigators. The incidences of AEs
that led to discontinuation were comparable between
aclidinium/formoterol FDC 400/12 μg (6.3%), aclidinium/
formoterol FDC 400/6 μg (6.6%), and placebo (6.3%), and
slightly lower in the aclidinium (4.7%) and formoterol
(4.2%) groups. The AE most commonly associated with
discontinuation was dyspnea, reported mostly in the placebo
group (0.9% placebo versus ≤0.6% in active treatment
arms).
Of the class-related AEs that may occur due to both
anticholinergic and β2-agonist mechanisms, only urinary
tract infection occurred in >2% of patients in any
treatment group (Table 2). The most common (>2%
and >placebo) potential anticholinergic AEs that occurred
with aclidinium/formoterol FDC 400/12 μg versus aclidinium
alone were dry mouth (2.4% versus 0.6%) and oropharyngeal
pain (2.1% versus 1.2%). The most common (>2% and
>placebo) β2-agonist AEs with aclidinium/formoterol
FDC 400/12 μg versus formoterol alone were cough
(5.1% versus 3.0%), headache (4.8% versus 3.6%), and
muscle spasm (2.7% versus 1.8%).
The overall incidence of serious AEs (SAEs) was low and
numerically higher in all active treatment arms compared
with placebo (5.7% aclidinium/formoterol FDC 400/12 μg,
5.4% aclidinium/formoterol FDC 400/6 μg, 5.0% aclidinium,
4.5% formoterol, and 3.6% placebo). Pneumonia, the most
common SAE, was reported by no more than 3 (0.9%)
patients in any randomized group (2 patients in the
aclidinium/formoterol FDC 400/12 μg group, 1 inaclidinium/formoterol FDC 400/6 μg, 1 in aclidinium,
3 in formoterol, and 3 in placebo); none of the reported
cases of pneumonia were considered treatment related.
Overall, 3 patients experienced an SAE that was considered
related to treatment (1 each in the placebo [atrial
fibrillation], aclidinium/formoterol FDC 400/12 μg
[pneumonitis], and formoterol groups [atrial fibrillation],
with only the placebo-treated patient discontinuing due
to the SAE).
The number of Major Adverse Cardiac Events (MACEs),
based on blinded adjudication, TEAEs and SAEs, were
infrequent and occurred at similar incidences across all
treatment groups. All adjudicated MACEs were SAEs with
the exception of 1 report of moderate nonfatal stroke in
the placebo group. Based on adjudicated SAEs, a total of
12 MACEs were reported for 12 patients. MACEs based
on adjudicated SAEs were reported in 2 (0.6%) and 4
(1.2%) patients in the aclidinium/formoterol FDC 400/12 μg
and 400/6 μg treatment groups. A total of 2 (0.6%)
patients in the placebo group, 1 (0.3%) patient in the
aclidinium group, and 3 (0.9%) patients in the formoterol
group reported MACEs. All MACEs were considered
unrelated to treatment.
A total of 5 deaths occurred during the treatment period
or within 30 days of the last dose of investigational product,
none of which were considered related to treatment.
One death occurred in the aclidinium/formoterol FDC
400/12 μg group, 3 in the aclidinium group, and 1 in the
formoterol group. Three of these deaths (1 each in the
aclidinium/formoterol FDC 400/12 μg, aclidinium, and
formoterol groups) were adjudicated as CV deaths (etiology
unknown). The other two deaths, both occurring in the
aclidinium group, were due to esophageal adenocarcinoma
and gastrointestinal necrosis.
Mean changes from baseline in clinical laboratory
parameters, vital signs, and ECGs were small and of no
clinical relevance. Holter monitoring did not show any
findings of an ECG effect for patients in any group, and
no differences were observed between the treatment
arms.
Discussion
An FDC comprising bronchodilators with complementary
mechanisms of action may improve lung function, while
offering patients the convenience of drug delivery via a
single device without increasing the risk for adverse
Figure 8 (See legend on next page.)
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Figure 8 Mean changes from baseline to week 24 in (A) E-RS overall average daily score over the study period, (B) nighttime symptom
severity, and (C) early morning symptom severity. Parenthetical values are the percent changes from baseline for the specified group. The
E-RS analysis was conducted using the ITT exacerbation population, defined as all randomized patients who received ≥1 dose of double-blind
study drug; the analyses of nighttime and early morning symptom severity were conducted using the general ITT population. For all outcomes,
mean changes were analyzed using a mixed-model for repeated measures. *p < 0.05 versus placebo; †p < 0.05 versus aclidinium and placebo;
§p < 0.05 versus aclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 12 μg;
ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400 μg and formoterol 6 μg; EMSCI, early morning symptoms of COPD instrument;
E-RS, EXACT respiratory symptoms; ITT, intention-to-treat; LS, least square; NiSCI, nighttime symptoms of COPD instrument.
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and LABAs has not been definitively determined, LABAs
have been shown to enhance the bronchodilatory effect of
LAMAs through a decrease in acetylcholine transmission
that leads to a reduction in bronchoconstriction, while
LAMAs amplify the effect of LABAs by blocking the
muscarinic receptors targeted by acetylcholine, resulting
in further bronchodilation [3,21,22]. Thus, a fixed-doseTable 2 Treatment-emergent adverse eventsa (≥2% in any tre
PBO (n = 332) ACL400/FOR1
FDC (n = 335)
Patients with ≥1 TEAE, n (%) 181 (54.5) 215 (64.2)
TEAEs by preferred term, n (%)
Coughb 12 (3.6) 17 (5.1)
Headacheb 11 (3.3) 16 (4.8)
Nasopharyngitis 12 (3.6) 16 (4.8)
Urinary tract infectionb,c 10 (3.0) 15 (4.5)
Back pain 9 (2.7) 10 (3.0)
Upper respiratory tract infection 5 (1.5) 10 (3.0)
Diarrhea 8 (2.4) 9 (2.7)
Muscle spasmsb 3 (0.9) 9 (2.7)
Sinusitis 7 (2.1) 9 (2.7)
Dry mouthc 1 (0.3) 8 (2.4)
Tooth abscess 2 (0.6) 8 (2.4)
Musculoskeletal pain 2 (0.6) 7 (2.1)
Oropharyngeal pain 10 (3.0) 7 (2.1)
Dizziness 7 (2.1) 6 (1.8)
Insomniab 2 (0.6) 6 (1.8)
Dyspnea 6 (1.8) 5 (1.5)
Nausea 4 (1.2) 5 (1.5)
Hypertensionb 6 (1.8) 4 (1.2)
Constipationb,c 6 (1.8) 3 (0.9)
Pain in extremity 0 3 (0.9)
Vomiting 2 (0.6) 3 (0.9)
Fatigue 8 (2.4) 2 (0.6)
Gastroenteritis viral 8 (2.4) 2 (0.6)
aPer protocol exacerbations of COPD were not considered an a priori safety outcom
TEAE; cPotential anticholiergic TEAE.
ACL 400, aclidinium 400 μg; ACL400/FOR12 FDC, fixed-dose combination of aclidini
of aclidinium 400 μg and formoterol 6 μg; FOR 12, formoterol 12 μg; PBO, placebo;combination of a LAMA and LABA is an important
therapeutic option, providing patients with more convenient
drug delivery and the potential for improved compliance.
In this trial, treatment with the LAMA/LABA fixed dose
combination of aclidinium/formoterol FDC 400/12 μg for
24 weeks resulted in statistically significant and clinically
meaningful improvements for the coprimary measures of
lung function: 1-hour morning postdose FEV1 versusatment group)
2 ACL400/FOR6
FDC (n = 333)
ACL400 (n = 337) FOR 12 (n = 332)
203 (61.0) 210 (62.3) 189 (56.9)
13 (3.9) 7 (2.1) 10 (3.0)
14 (4.2) 13 (3.9) 12 (3.6)
17 (5.1) 12 (3.9) 22 (6.6)
7 (2.1) 11 (3.3) 9 (2.7)
5 (1.5) 4 (1.2) 6 (1.8)
13 (3.9) 11 (3.3) 9 (2.7)
10 (3.0) 9 (2.7) 6 (1.8)
4 (1.2) 2 (0.6) 6 (1.8)
8 (2.4) 12 (3.6) 6 (1.8)
5 (1.5) 2 (0.6) 3 (0.9)
2 (0.6) 2 (0.6) 0
0 2 (0.6) 3 (0.9)
6 (1.8) 4 (1.2) 6 (1.8)
4 (1.2) 5 (1.5) 8 (2.4)
3 (0.9) 3 (0.9) 9 (2.7)
11 (3.3) 6 (1.8) 3 (0.9)
15 (4.5) 12 (3.6) 14 (4.2)
9 (2.7) 10 (3.0) 9 (2.7)
4 (1.2) 7 (2.1) 4 (1.2)
3 (0.9) 7 (2.1) 2 (0.6)
7 (2.1) 5 (1.5) 3 (0.9)
6 (1.8) 4 (1.2) 7 (2.1)
5 (1.5) 3 (0.9) 2 (0.6)
e and are therefore not included within the safety results; bPotential β2-agonist
um 400 μg and formoterol 12 μg; ACL400/FOR6 FDC, fixed-dose combination
TEAE, treatment-emergent adverse event.
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morning trough FEV1 versus formoterol (contribution of
aclidinium).
The coprimary endpoints in the AUGMENT COPD
study reported here reflect FDA guidance regarding fixed-
dose combination drugs (ie, each component of the fixed-
dose combination must make a contribution to the claimed
effects [23]). One aspect behind the rationale for combining
aclidinium and formoterol for this FDC was the difference
in time course for effective bronchodilation between the
two drugs. Formoterol was expected to provide a rapid
onset of action while the contribution of aclidinium was
expected to occur over many hours (at trough) [11,24].
The trial was thus powered to detect differences in the
prespecified coprimary endpoint comparisons: 1-hour
morning postdose FEV1 for the FDCs versus aclidinium
(to observe the early contribution of formoterol) and
trough FEV1 for the FDCs versus formoterol (to observe
the contribution of aclidinium over many hours). Any
other comparisons for these outcomes were considered
supportive in nature.
At study end, the aclidinium/formoterol 400/12 μg
FDC provided an additional 45 mL in trough FEV1 from
baseline (contribution of aclidinium), while the contribution
of formoterol to the FDC (aclidinium/formoterol FDC
400/12 μg versus aclidinium) was 28 mL, indicating that
aclidinium provided greater bronchodilation. Results for
trough FEV1 over the course of the study support the
endpoint observation that the contribution of formoterol
as a component of the FDC was smaller than that of
aclidinium. Additionally, trough FEV1 values for both
FDCs were numerically greater than aclidinium at all
timepoints throughout the study, a result that is supportive
of the observation that the FDCs provide greater
bronchodilation than either monotherapy component
alone.
Throughout the study, improvements in lung function
with aclidinium/formoterol FDC 400/12 μg, which were
numerically greater than those with aclidinium/formoterol
FDC 400/6 μg, were generally similar to the results observed
in a similarly designed study (ACLIFORM COPD) [25].
Results from this trial also demonstrate rapid bronchodilation
with aclidinium/formoterol FDC treatment (within 5 minutes
of dosing) that was sustained and clinically meaningful in
patients with COPD. Both aclidinium/formoterol FDCs
had safety profiles generally similar to that of each
monotherapy, though there were a numerically greater
percentage of FDC- and aclidinium-treated patients who
experienced any AE compared with those treated with
formoterol. The incidence of MACE was comparable
among all active treatment groups. Together, these results
indicate that treatment with a fixed-dose combination of
aclidinium/formoterol achieves a level of bronchodilation
greater than either monotherapy component and is well-tolerated in patients with moderate to severe COPD. The
therapeutic benefits on lung function derived from
treatment with the aclidinium/formoterol FDCs exceeded
the recommended MCID of 100 mL in 1-hour morning
postdose FEV1 versus placebo and were consistently
significantly greater than those of the monotherapies.
These improvements were observed from the first timepoint
assessed until the end of the study, demonstrating sustained
bronchodilation throughout 24 weeks of treatment.
Onset of bronchodilation (>15% increase from baseline
in FEV1) with aclidinium/formoterol FDC 400/12 μg was
observed as early as 5 minutes after the first dose, similar
to that of formoterol—a LABA known to have a fast onset
of action [26]. The improved efficacy with the aclidinium/
formoterol LAMA/LABA combination over the monotherapy
components and placebo may be attributed to complementary
pharmacodynamic profiles of these 2 bronchodilators:
direct bronchodilation by the β2-agonist, formoterol,
provides rapid onset of action, while reduction in
bronchoconstriction by the antimuscarinic, aclidinium,
prolongs duration of bronchodilation [24,27]. As rapid
onset of effect has been associated with better patient
compliance [28,29], the onset of action observed with the
aclidinium/formoterol FDCs may have a positive effect on
medication adherence in clinical practice.
Although spirometric outcomes are important in
assessing airflow obstruction in patients with COPD,
clinical measures of health status have been shown to
correlate better with symptoms such as breathlessness
[30,31]—one of the most troublesome symptoms of the
disease that often contributes to limitations in patients’
activities [30-32]. Following 24 weeks of treatment,
improvements in SGRQ total score exceeded the MCID
over placebo in patients treated with either aclidinium/
formoterol FDC 400/12 μg or aclidinium monotherapy.
Patients treated with aclidinium/formoterol FDC 400/12 μg
also experienced improvements in TDI focal score
that exceeded the MCID over placebo. Compared with
placebo, a significantly greater percentage of aclidinium/
formoterol FDC 400/12 μg and 400/6 μg-treated
patients reached the MCID for both SGRQ and TDI
at all study visits. These results support the clinical
benefit of aclidinium/formoterol FDCs in improving
health status and in reducing breathlessness, important
treatment goals for the effective management of COPD
[32].
A recently published review of the applicability of
MCIDs in COPD trials outlines numerous challenges
when comparing combination therapies to monotherapy
[33]. The authors indicate that improvements in various
outcome measures with combination therapy over
monotherapy should not be expected to exceed those of
monotherapy over placebo or to produce a result that would
reach an MCID. Further, the authors suggest that MCIDs or
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active agent to placebo may not be applicable to combination
therapy trials in which the comparison is to each
monotherapy component. It is not surprising that the
observed differences between monotherapy and placebo are
often greater than the differences between combination
therapy and the monotherapy components [34]. To
describe the additional proportion of patients who may
experience improvements at or above the MCID following
the addition of one active treatment to another, the
concept of a “minimum worthwhile incremental advantage”
has been proposed [33]. In light of the caveats inherent in
combination versus monotherapy trials, as well as the
recognition that patients may experience advantages with
combination therapy that are not readily measurable by
certain outcome criteria, it is reasonable to conclude that
the improvements in lung function and symptoms
observed with the aclidinium/formoterol FDCs over each
monotherapy in this trial may have clinical benefits for the
moderate to severe COPD patient.
Due to the circadian nature of cholinergic tone, more
impaired lung function is observed in the evening versus
daytime in patients with COPD [35]. This in turn may
be related to the prevalence of sleep disturbance in a
majority of patients with COPD [36,37], as well as
reports of nighttime and early morning being the worst
times of day for COPD patients due to breathlessness
and other symptoms [38]. Twice-daily aclidinium has
been shown to significantly improve lung function at
night compared with once-daily tiotropium [8], while
other twice-daily COPD medications, including formoterol,
reportedly improve nighttime symptoms [39-42]. In the
trial reported here, aclidinium/formoterol FDCs significantly
reduced both nighttime and early morning symptoms
compared with placebo—measured by the newly developed
NiSCI and EMSCI patient reported outcome measures—
while treatment with the monotherapy components
generally did not reach statistical significance in these
outcomes. The disparity between nighttime symptoms
outcomes with aclidinium monotherapy in this trial with
those in a previously conducted study [43] could be due
to the manner in which nighttime symptoms were
evaluated as both the NiSCI and the EMSCI are
currently undergoing empirical testing.
As the current study demonstrated that aclidinium/
formoterol administered in the morning significantly
improves bronchodilation as rapidly as 5 minutes postdose,
the evening dose of this twice-daily treatment may also
alleviate impaired airflow at night and reduce breathlessness,
potentially providing the added benefit of improving
COPD symptoms when they are at their worst. Further
analyses are necessary to correlate the clinically meaningful
treatment effect of the aclidinium/formoterol FDCs on lung
function with the positive effects on COPD symptoms.Conclusions
The spirometric and clinical outcomes from this study
demonstrate the sustained and improved efficacy of a
fixed-dose combination of aclidinium 400 μg/formoterol
12 μg over its monotherapy components. With a safety
profile generally similar to the aclidinium and formoterol
monotherapies, the results reported here support the
use of an aclidinium/formoterol FDC as maintenance
treatment for patients with moderate to severe COPD.
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